Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04447943 in stable sickle cell disease with or without hydroxyurea
NL-OMON44079Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edelinontrine in sickle cell disease (SCD) and sickle cell anemia (SCA) (4 arms), sponsored by Pfizer. Primary endpoint: Safety and tolerability. Started Jan 2016; status: active, not recruiting.
02
Drugs
edelinontrine
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on NL-OMON44079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44079.